Purpose: As shown in various studies 5-aminolevulinic acid (ALA) induces fluorescence of malignant and dysplastic bladder tissue and increases tumor detection rates by about 20%. However, data on the long-term benefits are sparse. Thus, the 5-year outcome data of a prospective randomized trial comparing patients who initially underwent bladder tumor resection (TUR) under standard white light or with ALA induced fluorescence were evaluated.
Materials And Methods: A total of 115 patients with suspected superficial bladder cancer were randomized to undergo standard or ALA assisted TUR. After the second look TUR at 6 weeks patients were followed for a median of 39 (standard) and 42 (ALA) months.
Results: Median time to first recurrence was 5 months in the standard and 12 months in the ALA group. Recurrence-free survival was 25% in the standard and 41% in the ALA group. The recurrence rate at 2, 12, 36 and 60 months after initial TUR was 41%, 61%, 73% and 75%, and 16%, 43%, 59% and 59% in the white light and ALA groups, respectively. The total number of recurrences was 82 in the standard and 61 in the ALA group. Tumor progression occurred in 9 patients in the standard and 4 in the ALA group. Cost analysis suggests a considerable economical advantage of ALA fluorescence assisted TUR compared to the standard procedure.
Conclusions: The initial advantage of improved tumor detection and decreased recurrence rates by ALA fluorescence assisted TUR is maintained for years, and effectively reduces morbidity and costs in patients with superficial bladder tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.ju.0000181814.73466.14 | DOI Listing |
Dermatol Surg
October 2024
All authors are affiliated with the Department of Dermatology, Oregon Health and Science University, Portland, Oregon.
Background: The melolabial interpolation flap is an effective surgical technique for reconstructing defects in the nasal ala and tip regions. Traditionally, this technique involves waiting for the standard 3-week period before pedicle division.
Objective: To evaluate whether accelerated takedown at 1- or 2-week postflap creation is possible while maintaining the flap's viability and functionality.
Animals (Basel)
November 2024
Department of Animal Nutrition, Faculty of Environmental Protection, University of Oradea, 1 University St., 410087 Oradea, Romania.
A ten-week study was conducted to investigate the effects of the dietary inclusion of HSC as a source of PUFAs together with a natural source of antioxidants such as DT or DTP on the performance of laying hens and egg quality, as well as the lipid profile, antioxidant content and oxidative stability of egg yolk before and after storage. A total of 96 laying hens (aged between 28 and 37 weeks) were divided into three groups of 32 birds each (eight replicate cages, four birds per cage) and were assigned randomly the following dietary treatments: a standard corn-soybean meal diet (C), a diet containing 20% hempseed cake and 4% dried whole tomato (HT) and a diet containing 20% hempseed cake and 4% dried tomato pomace (HTP). The incorporation of HSC and tomato waste (DT and DTP) into the diet of hens caused increases in feed intake ( < 0.
View Article and Find Full Text PDFAesthetic Plast Surg
December 2024
J.P. Hospital, Zirakpur, Punjab, India.
Background: Nasal ala defects present significant reconstructive challenges due to their complex anatomy and functional importance. Auricular composite grafts, incorporating both skin and cartilage, are particularly suited for this purpose because they can replace the multilayered structure of the nasal ala in a single surgical procedure, thereby restoring both form and function. Clinical outcomes of these grafts in the reconstruction of ala defects have been highly promising with studies indicating near complete survival rates.
View Article and Find Full Text PDFN Engl J Med
December 2024
From the Division of Haematology-Oncology (S.G., S.A., S.Z.), the Faculty of Medicine (S.G., S.A.), and the Department of Laboratory Medicine and Pathobiology, University of Toronto (M.S.), Toronto, and British Columbia Children's Hospital, University of British Columbia, Vancouver (A.M.L.) - all in Canada; Seattle Children's Hospital (R.E.R., T.H.-W., M.L.L.), the Ben Towne Center for Childhood Cancer and Blood Disorders Research and the Department of Pediatrics, Fred Hutchinson Cancer Center, University of Washington (R.E.R., M.L.L.), and Adaptive Biotechnologies (I.K.) - all in Seattle; the Department of Biostatistics, Colleges of Medicine, Public Health, and Health Professions, University of Florida, Gainesville (J.A.K., C.W., S.C.); the Division of Pediatric Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston (K.R.R.), Children's Blood and Cancer Center and Dell Children's Medical Center of Central Texas, Austin (H.R.K.), and the Department of Pediatrics, Division of Pediatric Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas (N.W.) - all in Texas; Servier Pharmaceuticals, Boston (A.L.A.); the Department of Genetics, University of Alabama at Birmingham, Birmingham (A.J.C.); Children's Hospital Colorado and the University of Colorado School of Medicine, Aurora (L.G., M.M.O.); the Division of Pediatric Hematology-Oncology, University of Utah, Primary Children's Hospital, Salt Lake City (J.L.M.); the Children's Oncology Group, Monrovia (O.M.), the Department of Pediatric Hematology-Oncology, MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach (M.O.), the Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles (B.L.W.), and Amgen, Thousand Oaks (F.Z.) - all in California; the Department of Pediatrics, Emory University School of Medicine, Atlanta (T.P.M.); the Steve and Cindy Rasmussen Institute for Genomic Medicine and the Biopathology Center, Nationwide Children's Hospital (S.C.R.) and the Biopathology Center and Children's Oncology Group Biospecimen Bank, Nationwide Children's Hospital (Y.M., E.W.) - both in Columbus, OH; Amgen Research, Munich, Germany (G.Z.); the Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN (M.D.); the Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine, University of Pennsylvania - both in Philadelphia (S.P.H., D.T.T.); and the Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York (E.A.R.).
Background: B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among children. The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National Cancer Institute) B-cell ALL in children may improve outcomes.
View Article and Find Full Text PDFShoulder Elbow
October 2024
Division of Shoulder and Elbow Surgery, Rothman Orthopaedics, Thomas Jefferson University, Philadelphia, PA, USA.
Introduction: is a common source of infection in shoulder surgery. 5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolite of that creates an exothermic reaction when activated by blue light. The purpose of this study was to evaluate the efficacy of preoperative photodynamic therapy using topical 5-ALA to decrease colonization.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!